JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran
koochak, Aghigh; Rakhshani, Nasser; Niya, Mohammad Hadi Karbalaie; Tameshkel, Fahimeh Safarnezhad; Sohrabi, Masoud Reza; Babaee, Mohammad Reza; Rezvani, Hamid; Bahar, Babak; Imanzade, Farid; Zamani, Farhad; Khonsari, Mohammad Reza; Ajdarkosh, Hossein; Hemmasi, Gholamreza;
  PDF(new window)
 Abstract
Background: The investigation of mutation patterns in oncogenes potentially can make available a reliable mechanism for management and treatment decisions for patients with colorectal cancer (CRC). This study concerns the rate of KRAS and BRAF genes mutations in Iranian metastatic colorectal cancer (mCRC) patients, as well as associations of genotypes with clinicopathological features. Materials and Methods: A total of 1,000 mCRC specimens collected from 2008 to 2012 that referred to the Mehr Hospital and Partolab center, Tehran, Iran enrolled in this cross sectional study. Using HRM, Dxs Therascreen and Pyrosequencing methods, we analyzed the mutational status of KRAS and BRAF genes in these. Results: KRAS mutations were present in 33.6% cases (n
 Keywords
Mutation analysis;KRAS;BRAF;metastatic colorectal cancer, pyrosequencing;high resolution melting;
 Language
English
 Cited by
1.
Sensitive High-Resolution Melting Analysis for Screening of KRAS and BRAF Mutations in Iranian Human Metastatic Colorectal Cancers,;;;;;;;;;;

Asian Pacific Journal of Cancer Prevention, 2016. vol.17. 12, pp.5147-5152 crossref(new window)
1.
Association between clinicopathological characteristics and RAS mutation in colorectal cancer, Modern Pathology, 2017, 1530-0285  crossref(new windwow)
 References
1.
Ahlquist T, Bottillo I, Danielsen SA, et al (2008). RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A. Neoplasia, 10, 680-6, 2 p following 686. crossref(new window)

2.
Allegra CJ, Jessup JM, Somerfield MR, et al (2009). American society of clinical oncology provisional clinical opinion:testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol, 27, 2091-6. crossref(new window)

3.
Amado RG, Wolf M, Peeters M, et al (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 26, 1626-34. crossref(new window)

4.
Andreyev HJ, Norman AR, Cunningham D, et al (2001). Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II' study. Br J Cancer, 85, 692-6. crossref(new window)

5.
Andreyev HJ, Norman AR, Cunningham D, et al (1998). Kirsten ras mutations in patients with colorectal cancer:the multicenter “RASCAL” study. J Natl Cancer Inst, 90, 675-84. crossref(new window)

6.
Bamford S, Dawson E, Forbes S, et al (2004). The COSMIC (catalogue of somatic mutations in cancer) database and website. Br J Cancer, 91, 355-8.

7.
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al (2007). Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res, 67, 2643-8. crossref(new window)

8.
Borras E, Jurado I, Hernan I, et al (2011). Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer, 11, 406. crossref(new window)

9.
Bos JL, Fearon ER, Hamilton SR, et al (1987). Prevalence of ras gene mutations in human colorectal cancers. Nature, 327, 293-7. crossref(new window)

10.
Campbell SL, Khosravi-Far R, Rossman KL, et al (1998). Increasing complexity of Ras signaling. Oncogene, 17, 1395-413. crossref(new window)

11.
Chen D, Wang YY, Chuai ZR, et al (2014). High-resolution melting analysis for accurate detection of BRAF mutations:a systematic review and meta-analysis. Sci Rep, 4, 4168.

12.
Ciardiello F, Tejpar S, Normanno N, et al (2011). Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Target Oncol, 6, 133-45. crossref(new window)

13.
De Roock W, De Vriendt V, Normanno N, et al (2011). KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol, 12, 594-603. crossref(new window)

14.
Deng G, Bell I, Crawley S, et al (2004). BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res, 10, 191-5. crossref(new window)

15.
Dolatkhah R, Somi MH, Bonyadi MJ, et al (2015). Colorectal cancer in iran: molecular epidemiology and screening strategies. J Cancer Epidemiol, 2015, 643020.

16.
Farina-Sarasqueta A, van Lijnschoten G, Moerland E, et al (2010). The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol, 21, 2396-402. crossref(new window)

17.
Fransen K, Klintenas M, Osterstrom A, et al (2004). Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis, 25, 527-33.

18.
French AJ, Sargent DJ, Burgart LJ, et al (2008). Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res, 14, 3408-15. crossref(new window)

19.
Guedes JG, Veiga I, Rocha P, et al (2013). High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. BMC Cancer, 13, 169. crossref(new window)

20.
Herreros-Villanueva M, Rodrigo M, Claver M, et al (2011). KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep, 38, 1315-20. crossref(new window)

21.
Hsieh LL, Er TK, Chen CC, et al (2012). Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. Clin Chim Acta, 413, 1605-11. crossref(new window)

22.
Imamura Y, Morikawa T, Liao X, et al (2012). Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res, 18, 4753-63. crossref(new window)

23.
Janakiraman M, Vakiani E, Zeng Z, et al (2010). Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res, 70, 5901-11. crossref(new window)

24.
Jemal A, Bray F, Center MM, et al. (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. crossref(new window)

25.
Kadowaki S, Kakuta M, Takahashi S, et al (2015). Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. World J Gastroenterol, 21, 1275-83. crossref(new window)

26.
Kwon MJ, Lee SE, Kang SY, et al (2011). Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffinembedded tissue. Pathol Res Pract, 207, 762-8. crossref(new window)

27.
Li HT, Lu YY, An YX, et al (2011). KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncol Rep, 25, 1691-7.

28.
Mahdavinia M, Bishehsari F, Ansari R, et al (2005). Family history of colorectal cancer in Iran. BMC Cancer, 5, 112. crossref(new window)

29.
Malekzadeh R, Bishehsari F, Mahdavinia M, et al (2009). Epidemiology and molecular genetics of colorectal cancer in iran: a review. Arch Iran Med, 12, 161-9.

30.
Naghibalhossaini F, Hosseini HM, Mokarram P, et al (2011). High frequency of genes' promoter methylation, but lack of BRAF V600E mutation among Iranian colorectal cancer patients. Pathol Oncol Res, 17, 819-25. crossref(new window)

31.
Negru S, Papadopoulou E, Apessos A, et al (2014). KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. BMJ Open, 4, 4652.

32.
Rajagopalan H, Bardelli A, Lengauer C, et al (2002). Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature, 418, 934. crossref(new window)

33.
Rizzo S, Bronte G, Fanale D, et al (2010). Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev, 36, 56-61. crossref(new window)

34.
Roth AD, Tejpar S, Delorenzi M, et al (2010). Prognostic role of KRAS and BRAF in stage II and III resected colon cancer:results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol, 28, 466-74. crossref(new window)

35.
Saridaki Z, Tzardi M, Papadaki C, et al (2011). Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >/= 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One, 6, 15980. crossref(new window)

36.
Schubbert S, Shannon K, Bollag G (2007). Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer, 7, 295-308. crossref(new window)

37.
Simi L, Pratesi N, Vignoli M, et al (2008). High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol, 130, 247-53. crossref(new window)

38.
Spindler KL, Lindebjerg J, Lahn M, et al (2009). Protein kinase C-beta II (PKC-beta II) expression in patients with colorectal cancer. Int J Colorectal Dis, 24, 641-5. crossref(new window)

39.
Vaughn CP, Zobell SD, Furtado LV, et al (2011). Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer, 50, 307-12. crossref(new window)

40.
Ye JX, Liu Y, Qin Y, et al (2015). KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. World J Gastroenterol, 21, 1595-605. crossref(new window)

41.
Yokota T, Ura T, Shibata N, et al (2011). BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer, 104, 856-62. crossref(new window)